Label: DONNATAL- phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet

  • NDC Code(s): 59212-425-04, 59212-425-10, 59212-425-11
  • Packager: Concordia Pharmaceuticals Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated September 22, 2017

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Donnatal® Tablets

    Each Donnatal® Tablet contains:

    Phenobarbital, USP..................................... 16.2 mg
    Hyoscyamine Sulfate, USP...................... 0.1037 mg
    Atropine Sulfate, USP .............................0.0194 mg
    Scopolamine Hydrobromide, USP ...........0.0065 mg

    Close
  • Inactive Ingredients

    Dibasic Calcium Phosphate Dihydrate, Compressible Sugar, Microcrystalline Cellulose, Sodium Starch Glycolate, Stearic Acid, Silicon Dioxide Colloidal, Magnesium Stearate.

    Close
  • CLINICAL PHARMACOLOGY

    This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.

    Close
  • INDICATIONS AND USAGE

    Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: "Possibly" effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.


    May also be useful as adjunctive therapy in the treatment of duodenal ulcer.


    Final classification of the less-than-effective indications requires further investigation.


    IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS.

    Close
  • CONTRAINDICATIONS

    • glaucoma;
    • obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy);
    • obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.);
    • paralytic ileus, intestinal atony of the elderly or debilitated patient;
    • unstable cardiovascular status in acute hemorrhage;
    • severe ulcerative colitis especially if complicated by toxic megacolon;
    • myasthenia gravis;
    • hiatal hernia associated with reflux esophagitis;
    • in patients with known hypersensitivity to any of the ingredients.

    Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

    Close
  • WARNINGS

    Donnatal® Tablets can cause fetal harm when administered to a pregnant woman. Animal reproduction studies have not been conducted with Donnatal® Tablets. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

    In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating).

    Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful.

    Donnatal® Tablets may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

    Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

    Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs.

    Since barbiturates are metabolized in the liver, they should be used with caution and initial doses should be small in patients with hepatic dysfunction.

    Close
  • PRECAUTIONS

    General

    Use with caution in patients with:

    • autonomic neuropathy
    • hepatic or renal disease
    • hyperthyroidism
    • coronary heart disease
    • congestive heart failure
    • cardiac arrhythmias
    • tachycardia
    • hypertension

    Belladonna alkaloids may produce a delay in gastric emptying (antral stasis) which would complicate the management of gastric ulcer.

    Do not rely on the use of the drug in the presence of complication of biliary tract disease.

    Theoretically, with overdosage, a curare-like action may occur.

    Information for Patients

    Donnatal® Tablets may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.

    Drug Interactions

    Phenobarbital may decrease the effect of anticoagulants, and necessitate larger doses of the anticoagulant for optimal effect. When the phenobarbital is discontinued, the dose of the anticoagulant may have to be decreased.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long-term studies in animals have not been performed to evaluate carcinogenic potential.

    Pregnancy

    Pregnancy Category D

    Animal reproduction studies have not been conducted with Donnatal® Tablets. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks (see WARNINGS).

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Donnatal® Tablets are administered to a nursing woman.

    Geriatric Use

    Elderly patients may react with symptoms of excitement, agitation, drowsiness, and other untoward manifestations to even small doses of the drug.

    Close
  • ADVERSE REACTIONS

    Adverse reactions may include xerostomia; urinary hesitancy and retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia; increased ocular tension; loss of taste sense; headache; nervousness; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; impotence; suppression of lactation; constipation; bloated feeling; musculoskeletal pain; severe allergic reaction or drug idiosyncrasies, including anaphylaxis, urticaria, and other dermal manifestations; and decreased sweating.

    Acquired hypersensitivity to barbiturates consists chiefly in allergic reactions that occur especially in persons who tend to have asthma, urticaria, angioedema, and similar conditions. Hypersensitivity reactions in this category include localized swelling, particularly of the eyelids, cheeks, or lips, and erythematous dermatitis. Rarely, exfoliative dermatitis (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis) may be caused by phenobarbital and can prove fatal. The skin eruption may be associated with fever, delirium, and marked degenerative changes in the liver and other parenchymatous organs. In a few cases, megaloblastic anemia has been associated with the chronic use of phenobarbital.

    Phenobarbital may produce excitement in some patients, rather than a sedative effect.

    To report SUSPECTED ADVERSE REACTIONS, contact Concordia Pharmaceuticals Inc. at 1-877-370-1142 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Close
  • DRUG ABUSE AND DEPENDENCE

    Abuse

    Phenobarbital may be habit forming and should not be administered to individuals known to be addiction prone or to those with a history of physical and/or psychological dependence upon drugs (see WARNINGS).

    Dependence

    In patients habituated to barbiturates, abrupt withdrawal may produce delirium or convulsions.

    Close
  • OVERDOSAGE

    The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, and CNS stimulation. Treatment should consist of gastric lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be used.

    Close
  • DOSAGE AND ADMINISTRATION

    The dosage of Donnatal® Tablets should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse effects.

    Donnatal® Tablets - Adults: One or two Donnatal® Tablets three or four times a day according to condition and severity of symptoms.

    Close
  • HOW SUPPLIED

    Donnatal® Tablets are supplied as: white, D-shaped, flat faced beveled edge tablets debossed “D” on one side and “Donnatal” on the other side.

    • Bottles of 100 tablets - NDC 59212-425-10.

    • Bottles of 1000 tablets - NDC 59212-425-11.
    • Bottles of 4 tablets - NDC 59212-425-04.

    Store at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Protect from light and moisture.

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

    Manufactured For:
    Concordia Pharmaceuticals Inc.
    St. Michael, Barbados BB11005
    www.donnatal.com

    Manufactured By:
    IriSys, LLC
    San Diego, CA 92121


    Revised: 3/15

    Close
  • PRINCIPAL DISPLAY PANEL

    NDC 59212-425-10 100 Tablets

    Donnatal®
    (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide)

    Each tablet contains:

    Phenobarbital, USP..................................... 16.2 mg
    Hyoscyamine Sulfate, USP...................... 0.1037 mg
    Atropine Sulfate, USP .............................0.0194 mg
    Scopolamine Hydrobromide, USP ...........0.0065 mg

    Rx only

    Keep this and all drugs out of reach of children.

    Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

    Protect from light and moisture.

    Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

    Adult Dosage and Administration: See accompanying prescribing information.

    Manufactured For:
    Concordia Pharmaceuticals Inc.
    St. Michael, Barbados BB11005
    www.donnatal.com

    Manufactured By:
    IriSys, LLC, San Diego, CA 92121

    DONT_IRI_BL_100

    Made in the United States

    Concordia Pharmaceuticals

    Donnatal label_100 tablets

    Close
  • INGREDIENTS AND APPEARANCE
    DONNATAL 
    phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:59212-425
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    PHENOBARBITAL (UNII: YQE403BP4D) (PHENOBARBITAL - UNII:YQE403BP4D) PHENOBARBITAL 16.2 mg
    HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X) HYOSCYAMINE SULFATE 0.1037 mg
    ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I) ATROPINE SULFATE 0.0194 mg
    SCOPOLAMINE HYDROBROMIDE (UNII: 451IFR0GXB) (SCOPOLAMINE - UNII:DL48G20X8X) SCOPOLAMINE HYDROBROMIDE 0.0065 mg
    Inactive Ingredients
    Ingredient Name Strength
    DIBASIC CALCIUM PHOSPHATE DIHYDRATE (UNII: O7TSZ97GEP)  
    SUCROSE (UNII: C151H8M554)  
    CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    STEARIC ACID (UNII: 4ELV7Z65AP)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    Product Characteristics
    Color white Score no score
    Shape SEMI-CIRCLE Size 8mm
    Flavor Imprint Code D;Donnatal
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:59212-425-10 100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 12/30/1980
    2 NDC:59212-425-11 1000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 12/30/1980
    3 NDC:59212-425-04 4 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 12/30/1980
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    unapproved drug other 12/30/1980
    Labeler - Concordia Pharmaceuticals Inc. (860243190)
    Close